[E-Daily Reporter Shin Ha-yeon ] The KOSDAQ Market Division of the Korea Exchange announced on the 13th that the eight-month improvement period for Icure Pharmaceutical Incorporation(175250)had ended as of the 12th.
The exchange stated, “The company must submit a report on the implementation of its improvement plan and a verification report from an expert regarding the results of the plan’s implementation within 15 business days of the end of the improvement period. The exchange plans to convene the Corporate Review Committee within 20 business days of the submission of these documents to decide whether to delist the company.”
If the company files an appeal, the KOSDAQ Market Committee will convene within 20 business days of receiving the appeal to decide on delisting (including whether to grant a remediation period).
The exchange stated, “The company must submit a report on the implementation of its improvement plan and a verification report from an expert regarding the results of the plan’s implementation within 15 business days of the end of the improvement period. The exchange plans to convene the Corporate Review Committee within 20 business days of the submission of these documents to decide whether to delist the company.”
If the company files an appeal, the KOSDAQ Market Committee will convene within 20 business days of receiving the appeal to decide on delisting (including whether to grant a remediation period).
